Vidofludimus calcium (IMU-838) is an oral small-molecule investigational therapy in late-stage development for multiple sclerosis and other chronic inflammatory/autoimmune diseases. Ongoing Phase 3 ENSURE trials in relapsing MS have top-line data expected by end of 2026, and additional progressive MS development is planned. It is not yet approved.
Immunic reported first-quarter 2026 results and said a $200 million upfront private placement is expected to fund phase 3 ENSURE trials in relapsing MS. The financing could provide up to $400 million in gross proceeds.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
Immunic announced an oversubscribed private placement of up to $400 million to complete phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a phase 3 program in primary progressive MS, and transition to a commercial organization.
Immunic announced an oversubscribed private placement of up to $400 million to complete Phase 3 trials of vidofludimus calcium in relapsing multiple sclerosis, initiate a Phase 3 trial in primary progressive MS, and transition into a commercial organization.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03722576 |
Vidofludimus Calcium for Primary Sclerosing Cholangitis |
COMPLETED | PHASE2 |
